V8 Peptides — Engineered Performance
Research Library
Ipamorelin History: From GHRPs to the Ghrelin Receptor
IpamorelinHistory

Ipamorelin History: From GHRPs to the Ghrelin Receptor

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How was ipamorelin developed? It is the end of a roughly twenty-year line of work. In 1981 researchers designed growth-hormone-releasing peptides starting from weakly active enkephalin analogs; in 1984 the hexapeptide GHRP-6 was characterized; in 1996 the pituitary and hypothalamic receptor those peptides act on was cloned; in 1999 its natural ligand, ghrelin, was purified from stomach. Ipamorelin was reported in 1998 as the product of a chemistry programme that sought a secretagogue with GH selectivity, and its distinguishing finding was that, unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol in the swine study reported. This article tells that story as a timeline. Supplied for laboratory research use only.

Most compounds arrive in a catalog without a past. Ipamorelin has a documented one, and reading it explains why researchers pick this peptide when they need a clean read-out of the GHRP-type receptor. The timeline below follows the primary papers rather than secondary retellings. Structure-level detail is covered separately in ipamorelin structure and synthesis; this piece is about the sequence of discoveries. Product facts come from the ipamorelin 10 mg product page, and the compound summary is in the ipamorelin research overview and what is ipamorelin.

A timeline in six steps

YearMilestoneSource
1981Peptides designed from weakly active [D-Trp2] and [D-Phe2] enkephalin analogs by iterative design, synthesis and testing; Tyr-D-Trp-Ala-Trp-D-Phe-NH2 was the most active at the timeMomany 1981
1984Hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 reported to release GH in vitro and in vivo without a concomitant release of LH, FSH, TSH or prolactinBowers 1984
1989In rat pituitary cells, GHRP-6 and GRF are shown to act through different receptors and to synergizeCheng 1989
1996A receptor for the GH secretagogues is cloned from pituitary and hypothalamusHoward 1996
1998Ipamorelin described as the first selective GH secretagogueRaun 1998
1999Ghrelin purified from rat stomach as the endogenous ligand of the receptor; ipamorelin bone-growth study in rats publishedKojima 1999; Johansen 1999

Two features of this timeline stand out. The peptides came first and the receptor second: the secretagogues were used as pharmacological probes for fifteen years before anyone had cloned their target. Howard and colleagues, in the abstract of the cloning paper, say the receptor was shown to be the target of the secretagogues and that it supported the notion that they mimic an undiscovered hormone (Howard 1996). Three years later that hormone was found (Kojima 1999).

From enkephalin analogs to the first hexapeptide

The 1981 paper is a useful example of cycle-based peptide design. Weak GH-releasing activity in two enkephalin analogs prompted conformational energy calculations, comparison of active and inactive analogs and the prediction of new sequences; progressively more active analogs were synthesized and tested, and the cycle was repeated until a series of very active compounds resulted (Momany 1981). The hexapeptide described in 1984 extended that line, and its abstract is notable for what it did not find: no concomitant release of LH, FSH, TSH or prolactin (Bowers 1984). That early claim of selectivity set the benchmark that later secretagogues were compared against.

The 1984 abstract also records practical properties that a laboratory still finds relevant: activity in several species, activity by several routes in rats, a time course in which GH rose within two minutes and had usually returned to baseline by two hours, and inhibition of the response by somatostatin. The same abstract reports that the response was longer in duration than that of the larger releasing factors compared. These are descriptions of what was observed in animals, not statements about any use.

Why a more selective compound was wanted

Selectivity is the thread that connects the early and late work. The GHRP family stimulates GH release, but members differ in what else they move. In the swine experiment reported with ipamorelin, GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, while ipamorelin did not release ACTH or cortisol to levels significantly different from those after GHRH stimulation, even at doses more than 200-fold above the ED50 for GH release (Raun 1998). None of the secretagogues tested affected FSH, LH, prolactin or TSH. On that basis the authors called ipamorelin the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH.

The same paper gives the potency picture in rat pituitary cells: ipamorelin released GH with a potency and efficacy similar to GHRP-6 (EC50 1.3 nmol/L against 2.2 nmol/L, and Emax 85% against 100%), and antagonist experiments supported action through a GHRP-like receptor rather than the GHRH receptor (Raun 1998). For a comparison against the neighbouring peptides, see ipamorelin vs GHRP-6 and ipamorelin vs GHRP-2.

The preclinical record after 1998

Follow-up animal work used ipamorelin as a tool to examine GH-axis questions in rats. In adult female rats, ipamorelin given subcutaneously three times daily for 15 days dose-dependently increased the longitudinal bone growth rate from 42 µm/day in the vehicle group to 44, 50 and 52 µm/day in the three exposed groups; the exposure did not change total IGF-I, IGFBPs or serum bone-formation and resorption markers, and the pituitary GH response to a provocative dose was only marginally reduced (Johansen 1999). In a three-month model, adult rats given a glucocorticoid with or without ipamorelin showed that the combination group had higher maximum tetanic tension of the calf muscles and a four-fold higher periosteal bone formation rate than the glucocorticoid-only group (Andersen 2001).

StudyModelWhat the abstract reports
Johansen 1999Adult female rats, 15 daysDose-dependent rise in longitudinal bone growth rate; no change in total IGF-I or IGFBPs
Andersen 20018-month-old female rats, 3 monthsHigher muscle tension and periosteal bone formation than glucocorticoid alone
Raun 1998Rat pituitary cells, rats, swineGH release with potency like GHRP-6; no ACTH or cortisol rise in swine

These are findings in rats. They do not support any statement beyond what was measured, and they were obtained with the specific routes and schedules of those papers, which this article reports only so the studies can be located and read.

Reading the early abstracts critically

Early peptide-pharmacology abstracts are compressed, and three cautions apply when citing them. First, potency numbers depend on the assay: an EC50 from rat pituitary cells and an ED50 from swine are different quantities and should not be compared across tables. Second, “selective” is always relative to a panel. The ipamorelin paper’s panel covered FSH, LH, prolactin, TSH, ACTH and cortisol in swine, so it supports selectivity over those hormones in that species and nothing wider (Raun 1998). Third, the phrase “in vitro and in vivo” in an old abstract does not identify the species. The 1984 paper lists rats, monkeys, lambs, calves and, under special conditions, chicks, and a reader citing it should name the species the specific statement refers to (Bowers 1984).

It also helps to keep a running table of which finding belongs to which molecule. The synergy and desensitization experiments belong to GHRP-6; the receptor cloning belongs to the receptor; ghrelin belongs to the natural ligand; and the selectivity and bone-growth findings belong to ipamorelin. Mixing these is the most common source of overstated claims in methods sections, and a short provenance table in the lab notebook prevents it.

How to use the history when planning experiments

The timeline suggests three practical habits. First, name the receptor correctly in the methods: the target is the receptor cloned in 1996 and later shown to bind ghrelin, so claims about the “GHRP receptor” and the “ghrelin receptor” refer to the same protein family (Howard 1996; Kojima 1999). Second, if a design compares ipamorelin with GHRP-6 or GHRP-2, include read-outs beyond GH, such as ACTH and cortisol in a system that has them, because selectivity is the distinguishing claim. Third, cite the primary paper for each property rather than a review, since the 1998 selectivity result came from one swine experiment.

For bench work the product page lists a 10 mg lyophilized vial with purity stated as ≥98% by HPLC and storage at 2–8 °C with −20 °C for long-term holding. Certificates, where published, are in the COA library, and the reconstitution calculator handles vial arithmetic. Related catalog items are on the shop page. All material is for laboratory research use only; not for human or animal consumption.

Frequently asked questions

When was ipamorelin first described?

In 1998, in a paper that presented it as the first selective growth hormone secretagogue and as the outcome of a chemistry programme.

What came before ipamorelin?

Enkephalin-derived GH-releasing peptides designed in 1981, then the hexapeptide GHRP-6 characterized in 1984, and research on the GHRP receptor through the 1990s.

Why is the 1996 receptor cloning important?

It identified the G-protein-coupled receptor in pituitary and hypothalamus targeted by the secretagogues, and supported the idea that they mimic an undiscovered hormone.

How was that hormone found?

In 1999 ghrelin was purified from rat stomach as a GH-releasing acylated peptide and identified as the natural ligand.

What made ipamorelin distinctive in the original paper?

In swine, GHRP-6 and GHRP-2 raised ACTH and cortisol, whereas ipamorelin did not, even at more than 200-fold the ED50 for GH release.

Is ipamorelin as potent as GHRP-6 in vitro?

In rat pituitary cells the paper reports similar potency and efficacy, with EC50 values of 1.3 and 2.2 nmol/L respectively.

Which receptor does it act on?

Antagonist experiments in the original paper showed it acts through a GHRP-like receptor and not the GHRH receptor.

What animal studies followed?

Rat studies on longitudinal bone growth over 15 days and on glucocorticoid-related muscle and bone endpoints over three months.

What does the product page state about form and purity?

A 10 mg lyophilized powder in a sealed clear glass research vial, with purity stated as ≥98% by HPLC.

Are these results a statement about use in people?

No. They are animal and cell findings from the cited papers, reported here so the studies can be found and read.

Related reading: Ipamorelin Mechanism: GHS Receptor Signaling Explained, Ipamorelin Pharmacokinetics: Half-Life Math and Studies, Ipamorelin Reconstitution Guide: Diluent and Molarity.

References

  1. Momany FA, et al. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology. 1981;108(1):31-39. doi:10.1210/endo-108-1-31
  2. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. doi:10.1210/endo-114-5-1537
  3. Cheng K, et al. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology. 1989;124(6):2791-2798. doi:10.1210/endo-124-6-2791
  4. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
  5. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
  6. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
  7. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. doi:10.1054/ghir.1999.9998
  8. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. doi:10.1054/ghir.2001.0239

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.